{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:07:59Z","timestamp":1791896879467,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pulmonary Arterial Hypertension (PAH) remains a therapeutic challenge, and the search continues for more effective drugs and drug combinations. We recently reported that deletion of the vasoactive intestinal peptide (VIP) gene caused the spontaneous expression of a PH phenotype that was fully corrected by VIP. The objectives of this investigation were to answer the questions: 1) Can VIP protect against PH in other experimental models? and 2) Does combining VIP with an endothelin (ET) receptor antagonist bosentan enhance its efficacy?<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Within 3 weeks of a single injection of monocrotaline (MCT, <jats:italic>s.c<\/jats:italic>.) in Sprague Dawley rats, PAH developed, manifested by pulmonary vascular remodeling, lung inflammation, RV hypertrophy, and death within the next 2 weeks. MCT-injected animals were either untreated, treated with bosentan (<jats:italic>p.o<\/jats:italic>.) alone, with VIP (<jats:italic>i.p<\/jats:italic>.) alone, or with both together. We selected this particular combination upon finding that VIP down-regulates endothelin receptor expression which is further suppressed by bosentan. Therapeutic outcomes were compared as to hemodynamics, pulmonary vascular pathology, and survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Treatment with VIP, every other day for 3 weeks, begun on the same day as MCT, almost totally prevented PAH pathology, and eliminated mortality for 45 days. Begun 3 weeks after MCT, however, VIP only partially reversed PAH pathology, though more effectively than bosentan. Combined therapy with both drugs fully reversed the pathology, while preventing mortality for at least 45 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>1) VIP completely prevented and significantly reversed MCT-induced PAH; 2) VIP was more effective than bosentan, probably because it targets a wider range of pro-remodeling pathways; and 3) combination therapy with VIP plus bosentan was more effective than either drug alone, probably because both drugs synergistically suppressed ET-ET receptor pathway.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1465-9921-12-141","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T07:29:25Z","timestamp":1320737365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension"],"prefix":"10.1186","volume":"12","author":[{"given":"Sayyed A","family":"Hamidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Z","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M","family":"Szema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Lyubsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya Ping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami I","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,1]]},"reference":[{"key":"1163_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.healun.2007.01.035","volume":"26","author":"RL Benza","year":"2007","unstructured":"Benza RL, Park MH, Keogh A, Girgis RE: Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant. 2007, 26: 437-446. 10.1016\/j.healun.2007.01.035.","journal-title":"J Heart Lung Transplant"},{"key":"1163_CR2","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M Humbert","year":"2004","unstructured":"Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med. 2004, 351: 1425-1436. 10.1056\/NEJMra040291.","journal-title":"N Engl J Med"},{"key":"1163_CR3","doi-asserted-by":"publisher","first-page":"L547","DOI":"10.1152\/ajplung.00546.2005","volume":"291","author":"SI Said","year":"2006","unstructured":"Said SI: Mediators and modulators of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2006, 291: L547-558. 10.1152\/ajplung.00546.2005.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1163_CR4","first-page":"H692","volume":"239","author":"B Meyrick","year":"1980","unstructured":"Meyrick B, Gamble W, Reid L: Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol. 1980, 239: H692-702.","journal-title":"Am J Physiol"},{"key":"1163_CR5","doi-asserted-by":"publisher","first-page":"L580","DOI":"10.1152\/ajplung.00281.2007","volume":"293","author":"NR Bauer","year":"2007","unstructured":"Bauer NR, Moore TM, McMurtry IF: Rodent models of PAH: are we there yet?. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L580-582. 10.1152\/ajplung.00281.2007.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1163_CR6","doi-asserted-by":"publisher","first-page":"L1013","DOI":"10.1152\/ajplung.00217.2009","volume":"297","author":"KR Stenmark","year":"2009","unstructured":"Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF: Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009, 297: L1013-1032. 10.1152\/ajplung.00217.2009.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1163_CR7","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1097\/PCC.0b013e3181c76db3","volume":"11","author":"KR Stenmark","year":"2010","unstructured":"Stenmark KR, Rabinovitch M: Emerging therapies for the treatment of pulmonary hypertension. Pediatr Crit Care Med. 2010, 11: S85-90.","journal-title":"Pediatr Crit Care Med"},{"key":"1163_CR8","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1152\/jappl.1985.58.5.1723","volume":"58","author":"PA Nandiwada","year":"1985","unstructured":"Nandiwada PA, Kadowitz PJ, Said SI, Mojarad M, Hyman AL: Pulmonary vasodilator responses to vasoactive intestinal peptide in the cat. J Appl Physiol. 1985, 58: 1723-1728.","journal-title":"J Appl Physiol"},{"key":"1163_CR9","first-page":"304","volume":"97","author":"T Saga","year":"1984","unstructured":"Saga T, Said SI: Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians. 1984, 97: 304-310.","journal-title":"Trans Assoc Am Physicians"},{"key":"1163_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2220\/biomedres.12.273","volume":"12","author":"JD Boomsma","year":"1991","unstructured":"Boomsma JD, Foda HD, Said SI: Vasoactive intestinal peptide (VIP) reverses endothelin-induced contractions of guinea pig trachea and pulmonary artery. Biomed Res. 1991, 12: 273-277.","journal-title":"Biomed Res"},{"key":"1163_CR11","first-page":"A708","volume":"2","author":"SA Hamidi","year":"2005","unstructured":"Hamidi SA, Dickmann KG, Mathew S, Said SI: Pulmonary hypertension in Fawn-hooded rats: Rapid induction with alveolar hypoxia, correlation with upregulation of endothelin receptors, and attenuation by vasoactive intestinal peptide. Proc Ame Thoracic Soc. 2005, 2: A708-","journal-title":"Proc Ame Thoracic Soc"},{"key":"1163_CR12","first-page":"L1047","volume":"268","author":"K Maruno","year":"1995","unstructured":"Maruno K, Absood A, Said SI: VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. Am J Physiol. 1995, 268: L1047-1051.","journal-title":"Am J Physiol"},{"key":"1163_CR13","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1172\/JCI17500","volume":"111","author":"V Petkov","year":"2003","unstructured":"Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 2003, 111: 1339-1346.","journal-title":"J Clin Invest"},{"key":"1163_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0167-0115(00)00174-9","volume":"93","author":"SI Said","year":"2000","unstructured":"Said SI, Dickman KG: Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide. Regul Pept. 2000, 93: 21-29. 10.1016\/S0167-0115(00)00174-9.","journal-title":"Regul Pept"},{"key":"1163_CR15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.106.681718","volume":"115","author":"SI Said","year":"2007","unstructured":"Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, Chen JJ, Waschek JA, Kort S: Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation. 2007, 115: 1260-1268.","journal-title":"Circulation"},{"key":"1163_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1196\/annals.1418.014","volume":"1144","author":"SI Said","year":"2008","unstructured":"Said SI: The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann N Y Acad Sci. 2008, 1144: 148-153. 10.1196\/annals.1418.014.","journal-title":"Ann N Y Acad Sci"},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"L880","DOI":"10.1152\/ajplung.00499.2005","volume":"291","author":"AM Szema","year":"2006","unstructured":"Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, Abdel-Razek T, Chen JJ, Waschek JA, Said SI: Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol. 2006, 291: L880-886. 10.1152\/ajplung.00499.2005.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1163_CR18","first-page":"A2516,","volume":"181","author":"N Gali\u00e9","year":"2010","unstructured":"Gali\u00e9 N: Effects of inhaled aviptadil (Vasoactive Intestinal Peptide) in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med. 2010, 181: A2516,-","journal-title":"Am J Respir Crit Care Med"},{"key":"1163_CR19","first-page":"967","volume":"231","author":"M Clozel","year":"2006","unstructured":"Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C: Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood). 2006, 231: 967-973.","journal-title":"Exp Biol Med (Maywood)"},{"key":"1163_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1183\/09031936.00105807","volume":"31","author":"SA Hamidi","year":"2008","unstructured":"Hamidi SA, Prabhakar S, Said SI: Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur Respir J. 2008, 31: 135-139. 10.1183\/09031936.00105807.","journal-title":"Eur Respir J"},{"key":"1163_CR21","first-page":"131","volume":"12","author":"ER Weibel","year":"1963","unstructured":"Weibel ER: Principles and methods for the morphometric study of the lung and other organs. Lab Invest. 1963, 12: 131-155.","journal-title":"Lab Invest"},{"key":"1163_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/76282","volume":"6","author":"KN Cowan","year":"2000","unstructured":"Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M: Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000, 6: 698-702. 10.1038\/76282.","journal-title":"Nat Med"},{"key":"1163_CR23","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1172\/JCI26593","volume":"115","author":"RJ Barst","year":"2005","unstructured":"Barst RJ: PDGF signaling in pulmonary arterial hypertension. J Clin Invest. 2005, 115: 2691-2694. 10.1172\/JCI26593.","journal-title":"J Clin Invest"},{"key":"1163_CR24","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1161\/CIRCULATIONAHA.104.524926","volume":"111","author":"C Guignabert","year":"2005","unstructured":"Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, Hamon M, Adnot S, Eddahibi S: Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005, 111: 2812-2819. 10.1161\/CIRCULATIONAHA.104.524926.","journal-title":"Circulation"},{"key":"1163_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/FJC.0b013e31802df112","volume":"49","author":"BH Jiang","year":"2007","unstructured":"Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H: Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol. 2007, 49: 85-89. 10.1097\/FJC.0b013e31802df112.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1163_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1161\/01.CIR.96.2.689","volume":"96","author":"Y Mitani","year":"1997","unstructured":"Mitani Y, Maruyama K, Sakurai M: Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation. 1997, 96: 689-697.","journal-title":"Circulation"},{"key":"1163_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1164\/rccm.200302-282OC","volume":"169","author":"RT Schermuly","year":"2004","unstructured":"Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, et al: Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004, 169: 39-45.","journal-title":"Am J Respir Crit Care Med"},{"key":"1163_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1164\/rccm.200703-349OC","volume":"177","author":"H Obata","year":"2008","unstructured":"Obata H, Sakai Y, Ohnishi S, Takeshita S, Mori H, Kodama M, Kangawa K, Aizawa Y, Nagaya N: Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am J Respir Crit Care Med. 2008, 177: 195-201.","journal-title":"Am J Respir Crit Care Med"},{"key":"1163_CR29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jtcvs.2004.03.003","volume":"128","author":"J Lu","year":"2004","unstructured":"Lu J, Shimpo H, Shimamoto A, Chong AJ, Hampton CR, Spring DJ, Yada M, Takao M, Onoda K, Yada I, et al: Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats. J Thorac Cardiovasc Surg. 2004, 128: 850-859. 10.1016\/j.jtcvs.2004.03.003.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1163_CR30","doi-asserted-by":"publisher","first-page":"L933","DOI":"10.1152\/ajplung.00310.2006","volume":"293","author":"MS McMurtry","year":"2007","unstructured":"McMurtry MS, Bonnet S, Michelakis ED, Haromy A, Archer SL: Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L933-940. 10.1152\/ajplung.00310.2006.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1163_CR31","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1513\/pats.200605-118SF","volume":"3","author":"NW Morrell","year":"2006","unstructured":"Morrell NW: Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?. Proc Am Thorac Soc. 2006, 3: 680-686. 10.1513\/pats.200605-118SF.","journal-title":"Proc Am Thorac Soc"},{"key":"1163_CR32","volume-title":"F1000 Biol Rep","author":"NW Morrell","year":"2010","unstructured":"Morrell NW: Genetics of pulmonary arterial hypertension: do the molecular findings have translational value?. F1000 Biol Rep. 2010, 2: 2010\/10\/16 edition"},{"key":"1163_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0967-2109(01)00126-0","volume":"10","author":"S Gunaydin","year":"2002","unstructured":"Gunaydin S, Imai Y, Takanashi Y, Seo K, Hagino I, Chang D, Shinoka T: The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine. Cardiovasc Surg. 2002, 10: 138-145. 10.1016\/S0967-2109(01)00126-0.","journal-title":"Cardiovasc Surg"},{"key":"1163_CR34","volume-title":"Proceedings of the American Thoracic Society","author":"SI Said","year":"2011","unstructured":"Said SI, Hamidi SA: The VIP Gene is a Dominant Modulator of the Pulmonary Circulation. Proceedings of the American Thoracic Society. 2011,"},{"key":"1163_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1183\/09031936.03.00038903","volume":"22","author":"P Dorfmuller","year":"2003","unstructured":"Dorfmuller P, Perros F, Balabanian K, Humbert M: Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003, 22: 358-363. 10.1183\/09031936.03.00038903.","journal-title":"Eur Respir J"},{"key":"1163_CR36","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nrg1432","volume":"5","author":"AD Roses","year":"2004","unstructured":"Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet. 2004, 5: 645-656.","journal-title":"Nat Rev Genet"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1465-9921-12-141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1465-9921-12-141\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1465-9921-12-141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T17:15:35Z","timestamp":1630516535000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/1465-9921-12-141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1186\/1465-9921-12-141","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"11 August 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"141"}}